Please sign in using the form to the left to access these resources.
Maertens Reprint Maertens J, Raad I, Petrikkos G, et al, for the Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.Clin Infect Dis. 2004;39:1563–1571.
One unit per package
(Limit 5 per month)
Walsh Reprint Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.N Engl J Med. 2004;351:1391–1402.
One unit per package
(Limit 5 per month)
No educational resources for patients are available at this time.
You can request a number of complimentary resources, where
available, including:
Patient Educational Materials
Disease Management Tools, and more
Signing in using the form to the left will give you access to educational resources for other products.
Access our archived eMedical Forum Webcasts, which are available for your viewing at any time.
Please sign in using the form to the left to access this service.
Important Product Information
CANCIDAS is indicated for:
Empirical therapy for presumed fungal infections in febrile neutropenic patients.
Treatment of candidemia and the following Candida infections: intraabdominal abscesses, peritonitis, and pleural space infections. CANCIDAS has not been studied in endocarditis, osteomyelitis, or meningitis due to Candida.
Treatment of esophageal candidiasis.
Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies (ie, amphotericin B, lipid formulations of amphotericin B, and/or itraconazole). CANCIDAS has not been studied as initial therapy for invasive aspergillosis.
CANCIDAS is contraindicated in patients with hypersensitivity to any component of this product.
Concomitant use of CANCIDAS with cyclosporine should be limited to patients for whom the potential benefit outweighs the potential risk.
COZAAR and HYZAAR are registered trademarks of E.I. du Pont de Nemours and Company, Wilmington, Delaware, USA
FOSAMAX PLUS D is a trademark of Merck & Co., Inc.
VYTORIN and ZETIA are registered trademarks of MSP Singapore Company, LLC. View the Merck/Schering-Plough privacy policy.
All other brand names are registered trademarks of Merck & Co., Inc.
MerckServices and MerckSource are registered trademarks of Merck & Co., Inc.
MerckProductServices and MerckMedicus are trademarks of Merck & Co., Inc.
Contact Us
Ask a Product-Related Question or Report an Adverse Event
Let us assist you with information and services related to Merck and its products. Get Started
The Merck National Service Center will be pleased to assist you Monday–Friday from 8:00 AM–7:00 PM ET. Adverse events and product-related emergencies will be handled at any time.
requires a 
requires a 
